Brensocatib shows consistent efficacy and safety across three prespecified subgroups in new data from landmark aspen study

—    insmed presented 11 abstracts at ats 2025 from across its respiratory portfolio, including data on arikayce® , tpip and health economics and outcomes research   — bridgewater, n.j. , may 21, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 new abstracts at the american thoracic society (ats) 2025 international conference, which took place may 18-21 in san francisco, including three prespecified subgroup analyses from the phase 3 aspen trial of brensocatib in non-cystic fibrosis bronchiectasis (ncfbe), signaling the consistency of efficacy and safety outcomes across diverse clinical profiles.
INSM Ratings Summary
INSM Quant Ranking